On Thursday's edition of Market Checkup, The Motley Fool's health-care focused show for investors, Fool health-care analyst David Williamson sheds some light on what's driving the biggest movers in the health-care space today.
Shares of Ariad Pharmaceuticals (NASDAQ: ARIA ) popped 8% today on word from British newspapers that Eli Lilly (NYSE: LLY ) , and possibly GlaxoSmithKline (NYSE: GSK ) , were interested in buying the biotech. To David however, the story just doesn't add up. In this segment, he looks at why the deal wouldn't make sense for Eli Lilly or Glaxo, and why he isn't putting a lot of credence behind these reports.
So what's the best way for investors to play the biotech space?
The best way to play the biotech space is to find companies that shun the status quo and, instead, discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.